BindingDB logo
myBDB logout

153 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28131714 119 Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-a/▀.EBI Novartis Institutes for BioMedical Research
1597853 2 A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1.EBI National Cancer Institute-Frederick
1992155 30 Design of potent protein kinase inhibitors using the bisubstrate approach.EBI URA CNRS 1309
2342075 11 Synthesis of quaternary amine ether lipids and evaluation of neoplastic cell growth inhibitory properties.EBI University of North Carolina
11454465 4 Synthesis of N-alkyl substituted indolocarbazoles as potent inhibitors of human cytomegalovirus replication.EBI GlaxoSmithKline
27117263 51 Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKC┐ inhibitors.EBI Takeda Pharmaceutical Co., Ltd
26762835 342 Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).EBI Icahn School of Medicine at Mount Sinai
25000588 72 Discovery of selective and orally bioavailable protein kinase C┐ (PKC┐) inhibitors from a fragment hit.EBI AbbVie Bioresearch Center
24684293 17 Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C┐ and┐ from typical C1 domains.EBI National Cancer Institute-Bethesda
23394126 170 Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).EBI Exelixis Inc
23398373 88 Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases.EBI Vertex Pharmaceuticals Inc
21251828 44 Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.EBI MSD
23103095 125 Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.EBI Abbott Laboratories
22726925 216 Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.EBI Cellzome Ltd
21797275 139 Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.EBI Novartis Institutes for BioMedical Research
22078216 146 2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.EBI Novartis Institutes for BioMedical Research
22625994 28 Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.EBI Kyoto University
22738630 76 Structure-based optimization of aminopyridines as PKC¿ inhibitors.EBI Vertex Pharmaceuticals Inc
20000469 179 Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.EBI Boehringer Ingelheim Pharmaceuticals Inc
20100661 21 Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C.EBI University of Houston
19703774 56 C-5 substituted heteroaryl-3-pyridinecarbonitriles as PKCtheta inhibitors: part II.EBI Wyeth Research
18183025 12060 A quantitative analysis of kinase inhibitor selectivity.EBI Ambit Biosciences
9677190 49 Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.EBI University of California
18434148 43 Synthesis and PKCtheta inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles.EBI Wyeth Research
18359226 50 Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.EBI Bristol-Myers Squibb Research and Development
18077363 314 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.EBI University of Oxford
17977729 40 Design and physicochemical properties of new fluorescent ligands of protein kinase C isozymes focused on CH/pi interaction.EBI Kyoto University
17935989 146 Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.EBI Abbott Laboratories
16876403 85 Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
16460940 13 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.EBI Hoffmann-La Roche Inc
15369389 4 Conformationally constrained analogues of diacylglycerol (DAG). 23. Hydrophobic ligand-protein interactions versus ligand-lipid interactions of DAG-lactones with protein kinase C (PK-C).EBI National Cancer Institute-Frederick
12672248 50 Kinase inhibitors: not just for kinases anymore.EBI Northwestern University
12166950 208 Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.EBI Millennium Pharmaceuticals Inc
8289196 7 New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C.EBI University of North Carolina
10999477 40 Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.EBI Kyoto University
10843211 38 Structure-activity relationship studies of flavopiridol analogues.EBI Mitotix Inc
 80 Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructureEBI TBA
15953730 13 RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.EBI Hoffmann-La Roche Inc
22014550 337 Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).EBI Ansaris
21975067 12 Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C.EBI University of Houston
22037378 31824 Comprehensive analysis of kinase inhibitor selectivity.EBI Ambit Biosciences
21705217 60 Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38a MAP kinase inhibitors.EBI Bristol-Myers Squibb Co.
21696964 12 Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.EBI Keio University
21035336 42 5-amino-pyrazoles as potent and selective p38a inhibitors.EBI Bristol-Myers Squibb Research and Development
20817520 40 Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.EBI Kyoto University
19654408 2521 AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).EBI Ambit Biosciences
16372404 1 Actin is the primary cellular receptor of bistramide A.EBI University of Chicago
20684591 87 Identification of orally available naphthyridine protein kinase D inhibitors.EBI Novartis Institutes for BioMedical Research
20346655 117 Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.EBI Abbott Laboratories
20153643 68 Optimization of 5-vinylaryl-3-pyridinecarbonitriles as PKCtheta inhibitors.EBI Wyeth Research
19854645 87 Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.EBI Wyeth Research
19926477 100 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.EBI Abbott Laboratories
19762237 58 First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors.EBI Wyeth Research
19682896 49 C-5 Substituted heteroaryl 3-pyridinecarbonitriles as PKCtheta inhibitors: Part I.EBI Wyeth Research
8176401 21 Anti-AIDS Agents, 11. Betulinic Acid and Platanic Acid as Anti-HIV Principles from Syzigium claviflorum, and the Anti-HIV Activity of Structurally Related TriterpenoidsEBI TBA
 4 Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CK IIEBI TBA
 5 Novel conformationally constrained analogues of diacylglycerol. Protein kinase C binding affinity of simplified compounds based on a 6-membered lactam moietyEBI TBA
 42 A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylationEBI TBA
 230 Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivativesEBI TBA
 99 Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitorsEBI TBA
 77 Synthesis and protein kinase C inhibitory activities of indane analogs of balanolEBI TBA
 70 Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moietyEBI TBA
 90 Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitorsEBI TBA
 107 Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors of protein kinase CEBI TBA
 40 Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanolEBI TBA
 40 Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanolEBI TBA
 75 Increasing the cellular PKC inhibitory activity of balanol: A study of ester analogsEBI TBA
 88 Novel PKC inhibitory analogs of balanol with replacement of the ester functionalityEBI TBA
 40 Protein kinase C inhibitory activities of balanol analogs bearing carboxylic acid replacementsEBI TBA
 7 Conformationally constrained analogues of diacylglycerol (DAG). 4. Interaction of α-alkylidene-γ-lactones with protein kinase C (PK-C)EBI TBA
19447612 59 Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCtheta inhibitors.EBI Wyeth Research
19438240 8 Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C.EBI University of Helsinki
19379015 40 Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.EBI National Cancer Institute-Frederick
19111463 46 Second generation 4-(4-methyl-1H-indol-5-ylamino)-2-phenylthieno[2,3-b]pyridine-5-carbonitrile PKCtheta inhibitors.EBI Wyeth Research
18606543 68 2-Alkenylthieno[2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKCtheta.EBI Wyeth Research
17875639 12 Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.EBI University of California San Francisco
18072722 42 Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes.EBI Kyoto University
17658776 109 Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.EBI Abbott Laboratories
17303421 56 Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.EBI Roche Research Center
17287122 79 Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.EBI Abbott Laboratories
16789733 41 Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16722637 39 Conformationally constrained analogues of diacylglycerol. 26. Exploring the chemical space surrounding the C1 domain of protein kinase C with DAG-lactones containing aryl groups at the sn-1 and sn-2 positions.EBI National Cancer Institute-Frederick
16682193 62 Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16640328 13 Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta.EBI Kyoto University
16216497 67 Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.EBI Abbott Bioresearch Center
16134942 19 Conformationally constrained analogues of diacylglycerol (DAG). 25. Exploration of the sn-1 and sn-2 carbonyl functionality reveals the essential role of the sn-1 carbonyl at the lipid interface in the binding of DAG-lactones to protein kinase C.EBI National Cancer Institute-Frederick
15771419 134 Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.EBI Johnson & Johnson Pharmaceutical Research & Development
15615512 21 Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15566298 34 The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.EBI Bristol-Myers Squibb Co.
15317463 16 Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
14552791 35 Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.EBI Eli Lilly and Company
12954072 46 New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity.EBI Georgetown University Medical Center
12941331 96 Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.EBI Johnson & Johnson Pharmaceutical Research & Development
12941324 66 Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.EBI Kyoto University
12824047 99 Novel IKK inhibitors: beta-carbolines.EBI Millennium Pharmaceuticals Inc
12749884 126 Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.EBI Eli Lilly and Company
12672234 64 Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.EBI Boehringer Ingelheim Pharmaceuticals Inc
12270156 8 Synthesis and kinase inhibitory activity of 3'-(S)-epi-K-252a.EBI Cephalon Inc
12039590 51 Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.EBI Abbott Bioresearch Center
11909733 30 Beta-carbolines as specific inhibitors of cyclin-dependent kinases.EBI Institute of Molecular and Cell Biology
11327599 25 Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth.EBI Georgetotwn University
11297449 3 Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta.EBI University of Tennessee College of Medicine
11266178 39 The amide hydrogen of (-)-indolactam-V and benzolactam-V8's plays a critical role in protein kinase C binding and tumor-promoting activities.EBI Kyoto University
11266177 26 The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.EBI Kyoto University
11206480 6 Synthesis of 7,8-disubstituted benzolactam-V8 and its binding to protein kinase C.EBI Institute of Organic Chemistry
11012021 69 Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.EBI BASF Bioresearch Corporation
10743939 63 Synthesis and biological activities of NB-506 analogues modified at the glucose group.EBI Banyu Tsukuba Research Institute
10636245 4 Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams.EBI University of Tokyo
10612598 29 4-Pyridin-5-yl-2-(3,4,5-trimethoxyphenylamino)pyrimidines: potent and selective inhibitors of ZAP 70.EBI Celltech Therapeutics Limited
10612590 56 Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
10498208 4 Protein kinase C modulators bearing dicarba-CLOSO-dodecaborane as a hydrophobic pharmacophore.EBI University of Tokyo
10397502 36 Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.EBI Stanford University
9554881 11 Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase Cdelta by synthesis of hydrophobically modified, teleocidin-mimicking benzolactams and computational docking simulation.EBI University of Tokyo
9135029 29 Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity.EBI Georgetown University Medical Center
9003521 249 Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.EBI Eli Lilly and Company
8709095 87 (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.EBI Eli Lilly and Company
26509640 234 Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.EBI AbbVie Bioresearch Center
24332494 16 Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer.EBI LEO Pharma A/S
23993332 8 Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.EBI LEO Pharma A/S
23803585 7 Effects of the methoxy group in the side chain of debromoaplysiatoxin on its tumor-promoting and anti-proliferative activities.EBI Kyoto University
23582444 20 Structure-activity studies on the side chain of a simplified analog of aplysiatoxin (aplog-1) with anti-proliferative activity.EBI Kyoto University
21388717 1 Glycoglycerolipid analogues inhibit PKC translocation to the plasma membrane and downstream signaling pathways in PMA-treated fibroblasts and human glioblastoma cells, U87MG.EBI University of Milan
7807122 4 New cytotoxic peroxylactones from the marine sponge, Plakinastrella onkodes.EBI Harbor Branch Oceanographic Institution, Inc.
17618015 13 Bioactive peroxides as potential therapeutic agents.EBI The Hebrew University of Jerusalem
10052965 9 Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent.EBI Universit£ Blaise Pascal
9572888 4 Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.EBI Universit£ Blaise Pascal
14505650 12 An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury.EBI Northwestern University
27731641 5 Isolation of Phorbol Esters from Euphorbia grandicornis and Evaluation of Protein Kinase C- and Human Platelet-Activating Effects of Euphorbiaceae Diterpenes.EBI Kaohsiung Medical University
30274941 36 A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model.EBI Astellas Pharma Inc.
29135244 5 Natural Products with Heteroatom-Rich Ring Systems.EBI University of Auckland
29578342 35 Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.EBI Yunnan University
29870245 39 Discovery of Novel Small-Molecule Inhibitors of NF-?B Signaling with Antiinflammatory and Anticancer Properties.EBI University of Colorado
29860841 140 ?-Arylidene Diacylglycerol-Lactones (DAG-Lactones) as Selective Ras Guanine-Releasing Protein 3 (RasGRP3) Ligands.EBI Seoul National University
28991459 71 Methyl 3-(3-(4-(2,4,4-Trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a Novel and Dual Malate Dehydrogenase (MDH) 1/2 Inhibitor Targeting Cancer Metabolism.EBI Dongguk University
27943581 8 Reverse Biosynthesis: Generating Combinatorial Pools of Drug Leads from Enzyme-Mediated Fragmentation of Natural Products.BDB The University of Sydney
27128528 42 Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.BDB Harvard Medical School
2176210 48 Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.BDB Ciba-Geigy Ltd
11454905 22 [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.BDB Eli Lilly and Company
11121615 32 Synthesis and in vitro opioid activity profiles of DALDA analogues.BDB Clinical Research Institute of Montreal
16236500 26 Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.BDB Johnson & Johnson Pharmaceutical
15689148 19 Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors.BDB Shanghai Institute of Materia Medica
15664516 21 Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases.BDB University of Dundee
15026054 55 Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum.BDB CNRS